在瘤学中使用切莱科西布:准COX-2/PGE2轴以重编程瘤免疫微环境并增强多式疗法
Boyang Kuang1,2, Kuan Yang1,2, Xiaoting Zhong1,2
1Department of Oncology, The First Affiliated Hospital, Gannan Medical University, Ganzhou, China.
Frontiers in pharmacology
|December 12, 2025
概括
选择性循环氧化酶-2 (COX-2) 抑制剂塞莱科西布,通过减少瘤生长和增强抗瘤免疫力,在癌症治疗中表现有前途. 需要进一步的试验来确认其在个性化癌症治疗策略中的安全性和有效性.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 切莱科西布是一种选择性循环氧化酶-2 (COX-2) 抑制剂,具有抗炎症和抗瘤特性.
- 由于其多方面的治疗潜力,其在瘤学中的作用正在扩大.
研究的目的:
- 审查最近在癌症中赛莱科克西布分子机制的进展.
- 探索赛莱科克西布在癌症治疗中的临床应用和协同效应.
主要方法:
- 关于瘤学中赛莱科克西布的临床前和临床研究的综合.
- 分析赛莱科西布对瘤细胞增殖,转移和瘤免疫微环境的影响.
主要成果:
- 赛莱科克西布通过向COX-2来抑制瘤细胞的增殖和转移.
- 它通过减少调节性T细胞 (Tregs) 和髓质衍生抑制细胞 (MDSCs) 来调节免疫微环境,同时激活细胞毒性T细胞.
- 切莱科克西布与化疗,放射治疗和免疫治疗具有协同作用,增强了免疫检查点阻塞的有效性.
结论:
- 塞莱科克西布具有显著的潜力,作为多模式癌症治疗的基石.
- 进一步的大规模试验对于验证长期安全性和针对个性化癌症治疗模式的生物标志物驱动应用至关重要.
相关概念视频
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Tumor Immunotherapy
1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
Cancer Therapies
9.8K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.8K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
459
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
459
Combination Therapies and Personalized Medicine
5.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.8K
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
1.0K
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
1.0K


